Evaluation of the MYCOPLASMA IST3 urogenital mycoplasma assay in an international multicentre trial

Ian Boostrom1, Yohan Bala2, Jelena Minic Vasic3, Jelena Gluvakov3, Emmanuel Chanard4, Andrew H. Barratt1, Kirsty Sands1,5, Edward Portal1, Laurence Devigne6, Lucy C. Jones1,7,8 and Owen B. Spiller *1,9

1Cardiff University, Division of Infection and Immunity, Department of Medical Microbiology, University Hospital of Wales, Cardiff, UK; 2bioMérieux Global Clinical Affairs, Marcy, L’Étoile, France; 3Public Health Institute, Pancevo, Serbia; *Cerballiance Rhône Alpes, Lyon, France; 5Department of Zoology, University of Oxford, Oxford, UK; 6bioMérieux, R&D Microbiology, La Balme-les-Grottes, France; 7Department of Integrated Sexual Health, Dewi Sant Hospital Cwm Taf Morgannwg University Health Board, Pontypridd, UK; 8HealthFirst Consulting, Research Division, Blackwood, UK; 9Public Health England, Bacterial Reference Department, London, UK

*Corresponding author. E-mail: SpillerB@cardiff.ac.uk

Received 19 February 2021; accepted 4 August 2021

Objectives: To evaluate the accuracy, susceptibility and specificity of MYCOPLASMA IST3, the next generation of the most popular culture-based in vitro diagnostic device designed to detect, identify and test the susceptibility of urogenital mycoplasma infections.

Methods: MYCOPLASMA IST3 was evaluated against culture- and molecular-based gold standard methodologies to detect, identify, enumerate and determine antimicrobial resistance for Mycoplasma hominis and Ureaplasma species in 516 clinical samples collected across France, Serbia and the UK. Sample types included vulvovaginal/endocervical or urethral swabs (dry swab or eSwab®), semen and urine samples, which included blinded analysis following addition of a panel of 80 characterized control strains.

Results: Overall species identification was excellent for both Ureaplasma spp. (98.4% sensitivity, 99.7% specificity) and M. hominis (95.7% sensitivity, 100% specificity) relative to combined colony morphology on agar and quantitative PCR standards. Non-dilution-based bacterial load estimation by the assay was accurate between 83.7% (M. hominis) and 86.3% (Ureaplasma spp.) of the time (increased to 94.2% and 100%, respectively, if ±10-fold variance was allowed) relative to colonies counted on agar. Resistance accuracy for Ureaplasma spp. varied from gold standards for only 11/605 of individual tests (major error rate = 1.8%) and for 14/917 individual tests for M. hominis (major error rate = 1.5%).

Conclusions: The redesigned MYCOPLASMA IST3 assay eliminated previous shortcomings by providing independent accurate resistance screening of M. hominis and Ureaplasma species, even in mixed infections, with CLSI-compliant thresholds. Specificity, sensitivity and enumeration estimates correlated closely with the confirmatory methods.

Introduction

Human urogenital mycoplasma infections were recognized as early as 1898 for Mycoplasma hominis1 and 1954 for Ureaplasma spp.2 By 1966, in vitro antimicrobial susceptibility studies were already being performed on these bacteria, with evidence of antimicrobial resistance.3 Despite the controversy underlying the role of these organisms as causative agents in urogenital4,5 and fertility6 pathogenesis, reports of antimicrobial resistance continue to increase annually. Some studies have examined population urogenital mycoplasma epidemiology on a scale of 10 000–37 000 samples,7-9 and because of the need for technical simplicity have relied on the use of culture-based, colour-changing assays that identify the species of mycoplasma infection and determine ‘antimicrobial resistance’ (e.g. growth of that species in the presence of a range of antibiotics set at threshold concentrations). All Mycoplasma and Ureaplasma species have evolved to have a reduced-size genome that necessitates a parasitic existence within the host to facilitate replication (due to breakages in several synthetic pathways). Thereby, the effective classes of antimicrobial agents are only those that disrupt DNA gyrase activity.
(fluoroquinolones) and those inhibiting prokaryotic protein synthesis (tetracyclines and members of the macrolide/lincosamide/streptogramin/ketolide or MLSK class).

Many of the currently commercially available identification and antimicrobial resistance-determining devices for urogenital mycoplasmas were designed prior to the international standardization of antimicrobial thresholds being set by CLSI in 2011. Additional design limitations in these devices (outlined in detail in the review by Beeton and Spiller; aside from inappropriate choice or concentration of antimicrobials tested, include obfuscation of resistance results in a mixed infection containing M. hominis (inherently resistant to macrolides) and Ureaplasma spp. (inherently resistant to lincosamides). They also lack the ability to determine whether bacterial load, internationally set as between 10^4 and 10^5 colour-changing units (CCUs), is compliant with the resistance threshold concentrations that have been validated by CLSI.

The MYCOPLASMA IST2 in vitro medical device represents the most commonly used assay for determining resistance in culturable urogenital mycoplasmas. We have evaluated the third generation of this device (MYCOPLASMA IST3), which has the significant improvement of separating growth of M. hominis from Ureaplasma spp. for independent evaluation of CLSI-compliant concentrations of appropriate antimicrobials (choice and concentration differs between the two species), against gold standard broth microdilution and PCR methodologies. Validation was performed on a range of samples including swabs (vulvovaginal, endocervical and urethral), semen samples and urine collected in multiple clinical centres in the UK, France and Serbia. Additionally, we evaluated the accuracy of a novel enumeration read-out added to the assay (proprietary technology that did not require serial sample dilution), relative to the number of colonies that grew from serially diluted samples inoculated on A7 agar to assess sample bacterial load. Given the infrequency of sufficient numbers of antimicrobial-resistant isolates being collected, a set of 80 characterized archived resistant and susceptible M. hominis and Ureaplasma spp. strains were also evaluated following evaluator-blinded addition to sterile samples known to be free of endogenous mycoplasmas. For rigorous determination of antimicrobial resistance accuracy reporting, WGS analysis was used to identify the underlying mechanisms of resistance.

Materials and methods

Clinical samples

Clinical samples were from patients attending urology, fertility or sexually transmitted infection (STI) clinics and were collected through regular screening or for confirmation of a diagnosis of urogenital mycoplasmas. Participants from the UK were recruited at attendance at an independent sexual healthcare provider, HealthFirst Consulting (ethics granted by Cardiff University School of Medicine Research Ethics Committee). Following informed consent, anonymized leftover urine samples and endocervical swab samples were utilized for this research. Semen, male first-catch urine, urethral swabs and cervical or vaginal swab samples from anonymized participants in France were left over from clinical samples sent to CERBAlliance, Rhone Alpes-Centre Est, Lyon; they were regarded as 'waste' and therefore exempt from participant consent requirement (law 2012-300 of 12 March 2012 on research involving humans). Urethral, vulvovaginal and endocervical swab samples were provided by participants in Serbia attending Pancevo Health Institute, Pancevo (ethical approval 01–615/4-2018 granted by the Public Health Institute of Pancevo).

Reference isolates

A panel of 80 isolated strains (15 Ureaplasma spp. and 65 M. hominis) from previously published clinical cohorts, as well as strains from the UROGEN study (IRAS 251053; 500 Welsh Sexual Health patients; O. B. Spiller and L. C. Jones, unpublished results), with known antimicrobial susceptibility or characterized resistance, were used as controls. These quality controls were coded (species and susceptibility unknown to the recipient) and aliquots containing 10^4 CCUs of viable bacteria were sent on dry ice to test facilities in France and the UK. These strains were kept at −80 °C until required, then they were thawed and added immediately to 1 mL aliquots of clinical samples prior to processing for the MYCOPLASMA IST3 (samples also run without ‘spiking’ in parallel to examine endogenous infection). Spiked and unspiked samples were processed as per the study design protocol.

Study protocol

All samples were provided with a sequential anonymized code based on the country of origin (CO01 for France, SO01 for Serbia, UO01 for Wales etc.). Data for all countries were recorded directly into the Medidata Rave web-based data capture platform. Initial data collected included sample type (semen, urine, vulvovaginal/endocervical swab, urethral swab), participant gender, date sample collected, swab type (dry swab, eSwab or not applicable) and the date (if applicable); further details are in the Supplementary Materials and methods, available as Supplementary data at JAC Online.

Following sample collection, contents from dry swabs were released by agitation into the R1 transport broth included in the assay, whereas 200 μL of transport medium from eSwabs or 200 μL of urine or semen were added and mixed with R1 for other sample types. Inoculated R1 broths have been validated to be stable without infectivity loss for 5 h at 18–25 °C or 48 h at 2–8 °C. With as short a delay as possible, the assay was set up and inoculated as per the manufacturer’s instructions (Supplementary Materials and methods and Figure S1a), starting with a suspension of 3 mL of R1 being added into the R2 vial containing lyophilized growth medium following the inoculation of three non-confluent 10 μL drops of the R1 + R2 suspension onto the surface of A7 agar (bioMérieux, France) for species identification and enumeration. The R1 + R2 vials were incubated alongside the assay and at the first observation of colour change, a 10-fold dilution series in growth medium was performed and frozen for transport to Cardiff University for quantitative PCR (qPCR) and MIC determination.

Gold standard comparison methods

Quality control for gold standards utilized the recommended strains ATCC 23114 (M. hominis), ATCC 27815 (Ureaplasma parvum) and ATCC 33175 (Ureaplasma urealyticum); they were used to evaluate each batch of MYCOPLASMA IST3 assay (bioMérieux), each batch of A7 agar (bioMérieux) and run in parallel during each experiment for determining the MIC for clinical samples. MICs were determined for all isolates using broth microdilution methods compliant with CLSI M45-A3 guidelines (thresholds detailed in Supplementary Materials and methods). Confirmation of species was performed by colony morphology determination on A7 agar, and by specific multiplex qPCR relative to a standardized plasmid containing defined copies of all primer/probe targets as previously published. Viability and quantification of M. hominis and Ureaplasma spp. in the initial clinical sample were determined by A7 agar (bioMérieux) colony enumeration. Plates were incubated microaerophilically at 37 °C and the two distinctive colony types were independently counted at ×100 magnification by light microscopy, in three non-overlapping fields per drop (nine fields). Average colony numbers were used to stratify bacterial load (>0 but <1 average colonies, 10^2 cfu/mL; 1–4 colonies, 10^3 cfu/mL; 5–15 colonies, 10^4 cfu/mL; and >15 colonies, 10^5 cfu/mL).
Validation values and statistical analysis

Sensitivity, specificity, positive predictive value and negative predictive value were calculated using a 2×2 contingency table and for each value a 2-sided CI was determined. The Electronic Data Capture (EDC) system Medidata Rave was used for data management activity, with direct entry at 0, 24 and 48 h timepoints, as well as for confirmatory data generated for qPCR and MIC at Cardiff University for calculation of accuracy. Significance was set at P<0.05 and analysis was carried out for each species independently. The antimicrobial susceptibility testing (AST) performance, as assessed by categorical agreement (CA, %), major error rate (ME, %) and very major error counts (VME, n), was calculated by comparing the MYCOPLASMA IST3 category (susceptible or resistant) with MIC results interpreted using CLSI M43-A interpretive breakpoints.

Underlying mechanisms of resistance

WGS was performed on an Illumina MiSeq with scaled-up cultures of Ureaplasma and Mycoplasma strains, following genomic DNA extraction as described in previously published methods for both reference and endogenous strains (see Supplementary Materials and methods and Table S1 for more details).

Results

Collected sample demographics

Clinical samples were collected from consenting participants in Wales (n=143), France (n=213) and Serbia (n=160). Sample types investigated included semen (n=88), male urine (n=142), urethral swab (n=26 by eSwab and n=30 by dry swab) and vulvovaginal or endocervical swab (n=61 by eSwab and n=169 by dry swab), as detailed in Table 1. A panel of 80 pre-characterized samples were also added (‘spiked’) into samples in an experimenter-blinded fashion, which included 7 antimicrobial-susceptible Ureaplasma spp. strains, 8 antimicrobial-resistant Ureaplasma strains (4 macrolide-resistant strains, 2 tetracycline-resistant strains and 2 fluoroquinolone-resistant strains), 49 antimicrobial-susceptible M. hominis strains and 16 antimicrobial-resistant M. hominis strains (2 moxifloxacin-resistant strains and 14 tetracycline-resistant strains).

MYCOPLASMA IST3 detection and identification of M. hominis and Ureaplasma spp.

Species identification by the MYCOPLASMA IST3 was compared with A7 agar identification by colony morphology18 for M. hominis (‘fried egg’, i.e. central colony with lower surrounding coronal dispersion across the surface of the agar) and Ureaplasma species (‘sea urchin’, i.e. small intense colony, visualization aided by brown precipitate, without colony corona), with discrepancies confirmed via qPCR. Overall, the accuracy of species identification was very high for both Ureaplasma spp. (98.4% sensitivity, 99.7% specificity) and M. hominis (95.7% sensitivity, 100% specificity), with minimal false positive or false negative results (Table 2). Furthermore, all samples spiked with viable characterized strains (15 Ureaplasma spp. and 65 M. hominis) were correctly identified. In total, 108 new Ureaplasma spp. isolates and 21 new M. hominis isolates were detected and collected from unspiked clinical specimens.

MYCOPLASMA IST3 enumeration of M. hominis and Ureaplasma spp.

The accuracy of the assay’s determination of bacterial load, which is a requirement for CLSI-compliant AST, was evaluated relative to colonies formed on an A7 agar measured at 24 and 48 h post-inoculation relative to colour change in the >10⁵ (Ureaplasma only), >10⁴ and >10⁶ cupules. This evaluates the capacity of the assay to estimate the number of bacteria per mL, in the absence of physical dilution; the data are presented in Table 3 and show that the assay and growth on agar were in complete agreement (agar colonies/mL rounded to nearest 10) between 83.7% (M. hominis) and 86.3% (Ureaplasma spp.) of the time and they were within one 10-fold dilution (i.e. within ±10 cfu/mL agreement) between 94.2% (M. hominis) and 100% (Ureaplasma spp.) of the time. Data were excluded for those samples where cfu/mL was out of the range of the assay or where other bacterial or fungal contamination growth obscured colony counting on an A7 agar.

MYCOPLASMA IST3 accuracy for detecting antimicrobial resistance

From the 516 samples collected, MICs of levofloxacin, moxifloxacin, tetracycline and clindamycin were determined for all 85 M. hominis-positive samples (endogenous and spiked) detected by the MYCOPLASMA IST3 assay, likewise, MICs of levofloxacin, moxifloxacin, tetracycline, erythromycin and telithromycin were determined for 124 Ureaplasma spp. strains (Table 4). These results were used to validate the prediction accuracy (Table 5) of antimicrobial resistance identified by the MYCOPLASMA IST3 assay. Comparison of the results for the 65 characterized M. hominis strains spiked into various negative sample types correctly identified all 15 strains carrying tet(M) resistance genes (MIC=16 or 32 mg/L). MYCOPLASMA IST3 also correctly identified two strains with resistance-mediating mutations in both the gyrA and parC genes.
genes for moxifloxacin (MIC = 4 mg/L) and levofloxacin (MIC = 8 mg/L) and correctly identified 49 fully susceptible control M. hominis strains. Clindamycin resistance was not found in any samples (control or endogenous strains), in full agreement with MIC values for all strains (maximum MIC = 0.125 mg/L). In 4 of the 21 samples with endogenous M. hominis, the M. hominis was tetracycline resistant [MIC = 32 or 64 mg/L, all carrying the tet(M) resistance gene], all from vulvovaginal or endocervical swabs: 1 from France and 3 from Serbia. Importantly, 17/21 of these samples were also positive for Ureaplasma spp. (i.e. a mixed infection) and the MYCOPLASMA IST3 assay correctly associated the tetracycline resistance only with the M. hominis infection, which the predecessor assay (MYCOPLASMA IST2) was unable to do. This is because the MYCOPLASMA IST3 has separate selective areas for each species that allows differential interrogation of antimicrobial susceptibility (see Figure S2 for further details).

MIC determination (Table 4) and assay performance for Ureaplasma spp. was similar (Table 5). Of the 15 characterized Ureaplasma spp. strains, MYCOPLASMA IST3 correctly identified the 2 tet(M)-positive strains (MIC = 16 mg/L). Two of the endogenous Ureaplasma spp. were found to have MICs above the resistance threshold (one at 2 mg/L and one at 4 mg/L), but the assay only identified growth at 1 mg/L for the latter strain at 24 h. However, neither of these strains was found to carry the tet(M) gene and the mechanism of these intermediate tetracycline MICs is unknown. The assay identified the only moxifloxacin-resistant sample (MIC = 8 mg/L), a vaginal/cervical swab sample from France (C031), correctly. The underlying resistance mechanism was identified by WGS as a dual mutation of S83L in ParC in combination with an E482K mutation in GyrB (no mutations in GyrA or ParE), which is adjacent to the QRDR identified for other bacteria (Figure S1). This strain also had a levofloxacin MIC of 32 mg/L that was also correctly identified by MYCOPLASMA IST3. Table 4 shows three Ureaplasma spp. isolates with a levofloxacin MIC of 4 mg/L (one characterized strain DF99 and two vaginal/cervical swab samples from Serbia; S084 and S138) and six isolates with a levofloxacin MIC of 2 mg/L (one characterized strain U6; one male urine (U052) from the UK; three vaginal/cervical swabs (C007, C079 and C105) from France; and one vaginal/cervical swab (S042) from Serbia). Four of these samples showed growth in the 2 mg/L cupule of the assay at 24 h and one also showed growth in the 4 mg/L cupule at 24 h, and all but one showed growth in the 2 mg/L cupule at 48 h, but this was 24 h after the ID well had turned positive. WGS data were available for 7/9 of all strains (not C007 or C079) with an MIC of 2 mg/L; they all had the S83L mutation in ParC, which was unable to mediate true resistance, i.e. MIC > 4 mg/L.

Finally, four characterized macrolide-resistant Ureaplasma strains were included for evaluation as spiked strains: three with dual 23S rRNA operon mutations A2058G (strains 234, 284 and 342; erythromycin MIC = 128 mg/L, telithromycin MIC = 16 mg/L) and one with a 6 bp deletion in the L4 accessory protein (O10; erythromycin MIC = 64 mg/L, telithromycin MIC = 0.125 mg/L). The Ureaplasma sector of the MYCOPLASMA IST3 assay correctly identified erythromycin resistance for all four strains and telithromycin resistance for three strains (the mutation in O10 leaves it susceptible to telithromycin). However, the selective agent for the Ureaplasma sector of the plate is also erythromycin; therefore, despite the absence of Mycoplasma in the sample, the assay also showed colour change for M. hominis ID cupules and the clindamycin cupules (as Ureaplasma spp. are inherently resistant). This pattern of growth has been identified in the manufacturer’s instructions as representing macrolide-resistant Ureaplasma in the absence of M. hominis and recommends further investigation by alternative methods.

Overall accuracy of the AST is presented in Table 5. For Ureaplasma spp., the highest ME rate was for levofloxacin (5/120; 4.2%) (discrepancy but MIC near threshold), with an overall ME rate across all antibiotics of 1.8%, and the only VME (complete discrepancy between MIC and assay) was found for one sample for tetracycline. For M. hominis, ME rates ranged from 0% to
1.5% (overall ME rate of 1.5%), with one VME for one sample for tetracycline and one sample for moxifloxacin.

Discussion

The MYCOPLASMA IST2 assay had been a market leader for evaluating *Ureaplasma* spp. and *Mycoplasma* presence and antimicrobial susceptibility since 2004. However, international guidelines instituted by the CLSI in 2011 necessitated an updated version of this assay. Beyond updating the choice and concentrations of the antimicrobials evaluated, the MYCOPLASMA IST3 can independently evaluate *Ureaplasma* spp. and *M. hominis* and provides cupules to evaluate bacterial load without the requirement for titration of the sample. Our evaluation against gold standard methodology in a multinational trial showed good performance for various types of clinical samples.

**Table 4.** MIC (mg/L) distribution for *Ureaplasma* spp. and *M. hominis*

| Isolate and antimicrobial | 0.015 | 0.03 | 0.06 | 0.125 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | MIC<sub>50</sub> | MIC<sub>90</sub> |
|---------------------------|-------|------|------|-------|------|-----|---|---|---|---|----|----|----|----|-------|-------|
| *Ureaplasma* spp., n (%)  |       |      |      |       |      |     |   |   |   |   |    |    |    |    |       |       |
| Levofloxacin              | 4     | 33   | 109  | 114   | 120  | 123 | |  |  |  |    |    |    |    | 124   | 100   |
| (3)                       |       | (27) | (88) | (92)  | (97) | (99) | | | | | | | | | (100) |
| Moxifloxacin              | 4     | 62   | 112  | 121   | 123  | 124 | | | | | | | | | (100) |
| (3)                       | (50)  | (59) | (98) | (99)  | (99) | (99) | | | | | | | | | (100) |
| Tetracycline              | 2     | 6    | 37   | 78    | 122  | 121 | | | | | | | | | (100) |
| (2)                       | (5)   | (30) | (63) | (90)  | (97) | (99) | | | | | | | | | (100) |
| Erythromycin              | 13    | 57   | 108  | 87    | 119  | 120 | | | | | | | | | | (100) |
| (10)                      | (46)  | (97) | (97) | (97)  | (97) | (97) | | | | | | | | | (100) |
| Telithromycin             | 44    | 80   | 103  | 118   | 121  | 124 | | | | | | | | | (100) |
| (35)                      | (65)  | (83) | (95) | (98)  | (98) | (100)| | | | | | | | | (100) |
| *M. hominis, n (%)        |       |      |      |       |      |     |   |   |   |   |    |    |    |    |       |       |
| Levofloxacin              | 9     | 46   | 82   | 83    | 85   | 85  | | | | | | | | | | (100) |
| (11)                      | (54)  | (96) | (97) | (97)  | (97) | (97) | | | | | | | | | (100) |
| Moxifloxacin              | 6     | 73   | 78   | 82    | 83   | 85  | | | | | | | | | | (100) |
| (7)                       | (86)  | (92) | (96) | (97)  | (97) | (100)| | | | | | | | | (100) |
| Tetracycline              | 52    | 54   | 60   | 66    | 70   | 79  | | | | | | | | | | (100) |
| (61)                      | (64)  | (71) | (78) | (82)  | (93) | (100)| | | | | | | | | (100) |
| Clindamycin               | 6     | 32   | 72   | 85    | 70   | 79  | | | | | | | | | | (100) |
| (7)                       | (38)  | (84) | (100)| | | | | | | | | | | | (100) |

The cumulative number of isolates is listed from lowest to highest dilution, with the cumulative percentage shown in brackets below. The isolates above the resistance threshold are shown in bold. MICs of antimicrobials were determined using broth microdilution methods as defined by the CLSI publication M43. The MIC<sub>90</sub> for tetracycline is skewed due to the large number of *tet(M)*-containing reference and endogenous strains present. Excluding *tet(M)* strains, the MIC<sub>90</sub> would be 0.5 mg/L.

The most valid comparisons as these are the only other two assays available that evaluate AST separately for *Ureaplasma* and *Mycoplasma* using CLSI-compliant antimicrobial concentrations. However, it should be noted that the other assays were evaluated relative to PCR detection, which detects non-viable bacteria in the samples.

Accuracy of the MYCOPLASMA IST3 to independently assess the susceptibility of the two species was of primary interest, as the absence of this ability was the major shortcoming of MYCOPLASMA IST2. Therefore, we supplemented investigation of WT infection of clinical samples from France, Serbia and the UK with known characterized (often fully genome-sequenced) susceptible and resistant strains, blinded to the staff performing the assay. All characterized *M. hominis* and *Ureaplasma* spp. (predominantly from previously published investigations) carrying the *tet(M)* resistance genes were identified correctly, in addition to four clinical *M. hominis* samples (19% WT prevalence of tetracycline resistance) with endogenous *tet(M)* and tetracycline resistance. Out of the 108 clinical samples with endogenous *Ureaplasma* spp., only 1 isolate was found to carry the *tet(M)* gene (MIC = 16 mg/L), as well as a second isolate with MIC = 2 mg/L (just at the threshold) that did not carry *tet(M)* resistance (2% WT prevalence of tetracycline resistance). The mechanism for this low-level resistance in the latter isolate was not identified.

No endogenous fluoroquinolone resistance was observed in the 21 clinical samples carrying *M. hominis*, but the MYCOPLASMA IST3 correctly identified both of the characterized strains carrying...
moxifloxacin/levofloxacin resistance–mediating mutations in both the gyrA and parC genes.\textsuperscript{19} Evaluating fluoroquinolone resistance in \textit{Ureaplasma} spp. was more complicated, but not due to the \textit{MYCOPLASMA IST3} assay. MIC determination of the combined endogenous and characterized strains identified one isolate (C031) with a levofloxacin MIC of 32 mg/L and a moxifloxacin MIC of 8 mg/L, which was correctly identified by the assay (resistance prevalence = 1%). This isolate was found to carry the S83L ParC mutation and a GyrB E482K mutation, which is very similar to a previously reported S83L/E482D dual mutation with MICs of 16 mg/L (levofloxacin) and 4 mg/L (moxifloxacin).\textsuperscript{21} Resistance to moxifloxacin has previously been noted to require a mutation in both the gyrase and topoisomerase genes for \textit{Streptococcus pneumoniae}, while levofloxacin resistance can be mediated by mutation in only one of these enzyme complexes.\textsuperscript{22} The location and alteration of amino acid charge are critical to mutations disrupting the tertiary structure elements of the QRDR of gyrA and parC,\textsuperscript{23} as well as gyrB and parE (the latter two being extrapolated from data on \textit{M. hominis} and \textit{Mycobacterium tuberculosis}).\textsuperscript{24,25} For \textit{Escherichia coli}, QRDR mutations are additive: S83L in GyrA gives a median 24-fold increase in ciprofloxacin MIC, while GyrA S83L \textsuperscript{!} ParC S80I gives a 62.5-fold increase (reviewed by van der Putten \textit{et al.}).\textsuperscript{26} However, we found the isolated \textit{Ureaplasma} spp. S83L ParC mutation altered the MIC of 0.5 mg/L (for five fully sequenced susceptible strains) to either 2 mg/L (intermediate resistant; four fully sequenced strains) or 4 mg/L (resistant; three fully sequenced strains). Moreover, no secondary SNP could be identified that was consistent for the 4 mg/L group. If we consider MIC > 2 mg/L as resistance, then the endogenous prevalence of levofloxacin resistance was the highest observed 8/108 (7.4%), while an additional mutation in gyrB was required for moxifloxacin resistance.

Finally, \textit{MYCOPLASMA IST3} correctly identified four characterized strains with erythromycin MICs of 64–128 mg/L that were incorporated (investigator-blinded) into the sample panels. However, telithromycin MIC was only elevated to 16 mg/L for isolates where the mechanism of resistance was due to A2058G

\begin{table}[h]
\centering
\caption{Summary of \textit{MYCOPLASMA IST3} AST accuracy}
\begin{tabular}{lcccccc}
\hline
Isolate and antimicrobial & Isolate status (BMD) & \multicolumn{2}{c}{Performance index} \\
 & & Total & S & R & CA, % (actual) & ME\textsuperscript{a}, % (actual) & VME\textsuperscript{b}, n \\
(\text{n}) & (\text{n}) & (\text{n}) & & & & & \\
\hline
\textit{Ureaplasma} spp. & & & & & & & \\
Levofloxacin & 124 & 120 & 4 & 96.0 (119/124) & 4.2 (5/120) & 0 \\
Moxifloxacin & 124 & 123 & 1 & 98.4 (122/124) & 1.6 (2/123) & 0 \\
Tetracycline & 124 & 120 & 4 & 97.6 (121/124) & 1.7 (2/120) & 1 \\
Erythromycin & 124 & 120 & 4 & 99.2 (123/124) & 0.8 (1/120) & 0 \\
Telithromycin & 125\textsuperscript{c} & 122 & 3\textsuperscript{d} & 99.2 (124/125) & 0.8 (1/122) & 0 \\
All drugs combined & 621 & 605 & 16 & 98.1 (609/621) & 1.8 (11/605) & 1 \\
\hline
\textit{M. hominis} & & & & & & & \\
Levofloxacin & 84 & 82 & 2 & 98.8 (83/84) & 1.2 (1/82) & 0 \\
Moxifloxacin & 84 & 81 & 3 & 97.6 (82/84) & 1.2 (1/81) & 1 \\
Tetracycline & 84 & 65 & 19 & 97.6 (82/84) & 1.5 (1/65) & 1 \\
Clindamycin & 84 & 84 & 0 & 100.0 (84/84) & 0.0 (0/84) & N/A \\
All drugs combined & 336 & 312 & 24 & 98.5 (331/336) & 1.0 (3/312) & 2 \\
All drugs and species combined & 957 & 917 & 40 & 98.2 (940/957) & 1.5 (14/917) & 3 \\
\hline
\end{tabular}
\end{table}

BMD, broth microdilution; S, susceptible; R, resistant; N/A, not applicable.
\textsuperscript{a}ME is defined as disagreement between MIC and assay regarding intermediate resistance and full resistance.
\textsuperscript{b}VME is defined as complete disagreement of assignment of strain as susceptible or resistant comparing MIC data with assay result.
\textsuperscript{c}125 \textit{Ureaplasma} spp. strains had telithromycin data available, while only 124 strains had data for all antimicrobials tested.
\textsuperscript{d}No resistant breakpoints are published and these isolates were found to be non-susceptible with MICs 32-fold higher than the maximum of the remaining \textit{Ureaplasma} spp. strains.
mutation in both 23S rRNA operons (data not shown), while strain O17 (where the mechanism of erythromycin resistance was a R66Q67 deletion in L4) was still susceptible to telithromycin (MIC = 0.125 mg/L relative to the MIC90 = 0.5 mg/L) as expected from previous research.27

In conclusion, the MYCOPLASMA IST3 assay was found to be extremely sensitive and specific for the identification of M. hominis and Ureaplasma spp., and has eliminated the largest inadequacies of its predecessor, MYCOPLASMA IST2, through its ability to accurately evaluate AST for both species independently in a mixed infection and compliance with CLSI resistance thresholds. The capacity to estimate bacterial load, in the absence of performing a dilution series of the sample, was surprisingly accurate. Concordance between true MIC determinations and growth in the cupwells was very high, although it suggests there may be some controversy in using S83L as a hallmark of fluoroquinolone resistance for Ureaplasma spp. However, the utility of the MYCOPLASMA IST3 assay may be limited in areas where macrolide-resistant Ureaplasma spp. (and potentially clindamycin-resistant M. hominis) become prevalent.

Acknowledgements
We would like to thank the participants of this study, administration and clinical staff of HealthFirst Consulting and Cwm Taf Morgannwg University Health Board for referring samples and isolates for analysis and for participating in clinical studies UROGEN (IRAS 2511053) and MYCO WELL D-ONE (IRAS 230693 & 253889) that provided many of the reference strains utilized to validate this assay. We would also like to thank Professor John Geen for supporting the KESS2 studentship programme that funded A.H.B. for his MPhil studies. These data were presented as a poster at the Thirtieth ECCMID congress (online due to COVID), 18–21 April 2020, Paris, France.

Funding
A.H.B. was supported by the Knowledge Economy Skills Scholarship 2 (KESS2) programme of funding (grant #80815) for his MPhil under the supervision of O.B.S. and L.C.J. Partial funding support for this project was provided by bioMérieux to O.B.S. and I.B.

Transparency declarations
Y.B. and L.D. are employees of bioMérieux. All other authors: none to declare.

Supplementary data
Supplementary Materials and methods, Results, Table S1 and Figures S1 and S2 are available as Supplementary data at JAC Online.

References
1 Dienes L, Edsall G. Observations on the L-organism of Kleineberger. Proc Soc Exp Biol Med 1937; 36: 740–4.
2 Shepard MC. The recovery of pleuropneumonia-like organisms from Negro men with and without nongonococcal urethritis. Am J Syph Gonorrhea Vener Dis 1954; 38: 113–24.
3 Shepard MC, Lunceford CD, Baker RL. T-strain Mycoplasma: selective inhibition by erythromycin in vitro. Br J Vener Dis 1966; 42: 21–4.
4 Horner P, Danders G, Cusini M et al. Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum in men and women? – a position statement from the European STI Guidelines Editorial Board. J Eur Acad Dermatol Venereol 2018; 32: 1845–51.
5 Plummer EL, Vodstrcil LA, Bodiyabadu K et al. Are Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasmaparvum associated with specific genital symptoms and clinical signs in non-pregnant women? Clin Infect Dis 2021; ciaa601.
6 Beeton ML, Payne MS, Jones L. The role of Ureaplasma spp. in the development of nongonococcal urethritis and infertility among men. Clin Microbiol Rev 2019; 32: e00137-18.
7 Huang C, Long X, Jing S et al. Ureaplasma urealyticum and Mycoplasma hominis infections and semen quality in 19,098 infertile men in China. World J Urol 2016; 34: 1039–44.
8 Ye G, Jiang Z, Wang M et al. The resistance analysis of Ureaplasma urealyticum and Mycoplasma hominis in female reproductive tract specimens. Clin Biochem Biophys 2014; 68: 207–10.
9 De Francesco MA, Caracciolo S, Bonfanti C et al. Incidence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum isolated in Brescia, Italy, over 7 years. J Infect Chemother 2013; 19: 621–7.
10 CLSI. Methods for antimicrobial susceptibility testing for human mycoplasmas—First edition: M43-A, 2011.
11 Waites KB, Duffy LB, Bébère CM et al. Standardized methods and quality control limits for agar and broth microdilution susceptibility testing of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum. J Clin Microbiol 2012; 50: 3542–7.
12 Beeton ML, Spiller OB. Antibiotic resistance among Ureaplasma spp. isolates: cause for concern? J Antimicrob Chemother 2017; 72: 330–7.
13 Pereyre S, Gonzalez P, De Barbeyrac B et al. Mutations in 23S rRNA account for intrinsic resistance to macrolides in Mycoplasma hominis and Mycoplasma fermentans and for acquired resistance to macrolides in M. hominis. Antimicrob Agents Chemother 2002; 46: 3142–50.
14 Harrison HR, Riggin RM, Alexander ER et al. In vitro activity of clindamycin against strains of Chlamydia trachomatis, Mycoplasma hominis, and Ureaplasma urealyticum isolated from pregnant women. Am J Obstet Gynecol 1984; 149: 477–80.
15 Morris DJ, Jones LC, Davies RL et al. MYCO WELL D-ONE detection of Ureaplasma spp. and Mycoplasma hominis in sexual health patients in Wales. Eur J Clin Microbiol Infect Dis 2020; 39: 2427–40.
16 Beeton ML, Chalker VJ, Jones LC et al. Antibiotic resistance among clinical Ureaplasma isolates recovered from neonates in England and Wales between 2007 and 2013. Antimicrob Agents Chemother 2016; 60: 52–6.
17 Beeton ML, Chalker VJ, Maxwell NC et al. Concurrent titration and determination of antibiotic resistance in Ureaplasma species with identification of novel point mutations in genes associated with resistance. Antimicrob Agents Chemother 2009; 53: 2020–7.
18 Brötman NL, Floyd CM, Johnson CA et al. Comparison of commercially available media for detection and isolation of Ureaplasma urealyticum and Mycoplasma hominis. 1992; 30: 1335–7.
19 Chalker VJ, Sharratt MG, Rees C et al. Tetracycline resistance mediated by tet(M) has variable integrative conjugative element composition in Mycoplasma hominis isolated in the United Kingdom from 2005 to 2015. Antimicrob Agents Chemother 2021; 65: e02513-20.
20 Redelinghuys MJ, Ehlers MM, Dreyer AW et al. Comparison of the new Mycofast Revaluation assay with a molecular assay for the detection of genital mycoplasmas from clinical specimens. BMC Infect Dis 2013; 13: 453.
21 Yang T, Pan L, Wu N et al. Antimicrobial resistance in clinical Ureaplasma spp. and Mycoplasma hominis and structural mechanisms underlying quinolone resistance. Antimicrob Agents Chemother 2020; 64: e02560–19.
ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43: 302–6.

Kawai Y, Nakura Y, Wakimoto T et al. In vitro activity of five quinolones and analysis of the quinolone resistance-determining regions of gyrA, gyrB, parc, and parE in Ureaplasma parvum and Ureaplasma urealyticum clinical isolates from perinatal patients in Japan. Antimicrob Agents Chemother 2015; 59: 2358–64.

Maruri F, Sterling TR, Kaiga AW et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 2012; 67: 819–31.

Bébéar CM, Renaudin H, Charron A et al. Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro. Antimicrob Agents Chemother 1998; 42: 2304–11.

van der Putten BCL, Remondini D, Pasquini G et al. Quantifying the contribution of four resistance mechanisms to ciprofloxacin MIC in Escherichia coli: a systematic review. J Antimicrob Chemother 2019; 74: 298–310.

Kostopoulou ON, Petropoulos AD, Dinos GP et al. Investigating the entire course of telithromycin binding to Escherichia coli ribosomes. Nucleic Acids Res 2012; 40: 5078–87.